Gout Therapeutics Market Size, Share, Opportunities, And Trends By Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents, Others), By Disease Condition (Acute Gout, Chronic Gout), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), And By Geography - Forecasts From 2023 To 2028

The gout therapeutics market was valued at US$1.521 billion in 2021 and is expected to grow at a CAGR of 8.04% during the forecast period.

Gout therapeutics are treatments specifically designed to manage and alleviate the symptoms of gout, a form of arthritis caused by the buildup of uric acid crystals in the joints. The rising prevalence of gout along with the changing lifestyle and higher prevalence of obesity are major growth drivers of the gout therapeutics market. Moreover, the ongoing research and product launches coupled with government support and rising awareness among people are further expected to boost the gout therapeutics market size.

Rising Prevalence of Gout

The prevalence of gout has been on the rise globally. The growing number of gout patients creates a demand for effective therapeutics, driving the gout therapeutics market growth. According to an article published in the Annals of Rheumatic Diseases in June 2021. In a countrywide cohort study that used data from the Clinical Practice Research Datalink, it was shown that the prevalence rate of gout had climbed from 0.98% in 1997 to 2.33% in 2021, spanning the COVID-19 pandemic.

Increasing Prevalence of Obesity

Obesity and gout are interconnected conditions, and obesity is recognized as a significant risk factor for developing gout. Uric acid levels rise as a result of increased uric acid synthesis and decreased uric acid excretion in individuals who are overweight, particularly those who are abdominally obese. Therefore the rising prevalence of obesity worldwide is contemplated to aid the gout therapeutics market. For instance, according to WHO, obesity is now an epidemic being the cause of around 2.8 million deaths each year. According to the World Obesity Atlas 2022 published by World Obesity Federation, it is estimated that 1 in 5 women and 1 in 7 women will live with obesity by 2030. 

Changing Lifestyle

Lifestyle factors play a crucial role in the development, management, and prevention of gout. Certain lifestyle choices such as dietary choices, alcohol consumption, smoking, and stress can contribute to the onset of gout or exacerbate its symptoms. Alcohol, particularly beer, and spirits, has been associated with an increased risk of gout. According to data on beer shipments and U.S. Census population statistics, individuals aged 21 and above in the United States consumed an average of 26 gallons of beer and hard cider per person in 2020. Thus, the huge consumption of beer and changing lifestyle such as the adoption of a sedentary lifestyle is one of the major growth drivers of the gout therapeutics market.

Increasing Awareness and Diagnosis

Increased awareness about gout among healthcare professionals and the general population has led to better diagnosis rates. Early and accurate diagnosis of gout enables timely initiation of treatment, promoting the demand for gout therapeutics. For instance, five self-management techniques are advised by the CDC's Arthritis Program for treating arthritis and related symptoms and these may also be beneficial for gout. Additionally, May 22 is celebrated as a Gout Awareness Day in America to raise public awareness about its adverse effects and its treatment. Several organizations have formed that raise gout awareness such as the National Gout Education Society, Alliance for Gout Awareness, and American Association of Kidney Patients. This rising awareness and institutional efforts are propelling the gout therapeutics market growth.

Increasing Research and Studies in the Field

The increasing number of studies and clinical trials for gout treatment followed by product launches are anticipated to boost the gout therapeutics market growth. For instance, D-0120 is under phase II clinical development for gouty arthritis, developed by InventisBio. Moreover, the phase 3 Dissolve program of SEL-212 developed by Selecta Biosciences to treat chronic refractory gout ended in March 2023. There is a statistically significant higher response rate in patients 50 years and above at the high dose in Dissolve I and Dissolve II.

Restraints in the Market

The gout therapeutics market has experienced growth and development however some restraints or challenges can impact its expansion. For example, gout demands long-term care and lifestyle change. However, some patients have trouble adhering to their treatment plans, which may include taking their medications as prescribed, changing their diets, and leading healthy lives. The effectiveness of gout therapies may be compromised by non-compliance since it might raise the risk of disease development and result in insufficient symptom management for gout. Moreover, the adverse effects of gout therapeutics can range from minor to serious which may limit the market growth. For instance, corticosteroids may have systemic adverse effects when used over an extended period.

North America is Expected to Grow Significantly

North America is expected to hold a significant share of the gout therapeutics market during the forecast period. The factors attributed to such a share are the rising incidence of gout, the existence of a strong healthcare system, and the rising healthcare expenditure. For instance, health expenditure as a percentage of US GDP increased from 16.68% in 2019 to 18.82% in 2020 as per the World Bank data. Moreover, the presence of major market players such as Merck & Co. and Mayo Clinic is further expected to bolster the gout therapeutics market in the region through enhanced products. 

Major Market Players

• Novartis AG is a global pharmaceutical company headquartered in Switzerland. It is one of the largest pharmaceutical companies in the world, operating in multiple therapeutic areas including cancer, chronic kidney disease, immunology, and gout.
• Horizon Therapeutics Plc is a biopharmaceutical company specializing in the development and commercialization of medicines for rare diseases and rheumatic conditions. It provides Krystexxa (pegloticase), a medicine for the treatment of adult patients with chronic gout who have not responded to or are unable to tolerate traditional medicines.
• AstraZeneca Plc is a multinational pharmaceutical company with a focus on the research, development, and commercialization of prescription drugs across various therapeutic areas. It provides Zurampic® for the treatment of hyperuricemia associated with gout in patients.

Key Market Developments

• In August 2022, Synglogic Inc. launched a new drug candidate SYNB2081 for gout treatment in collaboration with Ginkgo Bioworks. It is designed to lower uric acid developed through synthetic biology.
• In November 2021, Allena Pharmaceuticals was granted the FDA fast-track designation for its urate-degrading enzyme, ALLN-346 to treat hyperuricemia in gout patients with advanced chronic kidney disease.
• In January 2021, Febuxostat Tablets, a therapeutically similar generic form of Uloric (Febuxostat) Tablets, were introduced in the United States by Dr. Reddy's Laboratories Ltd. The bottles of 30 pills each contain two strengths of the tablets: 40 mg and 80 mg.

Segmentation:

• By Drug Class
  • NSAIDs
  • Corticosteroids
  • Colchicine
  • Urate-Lowering Agents
  • Others
• By Disease Condition
  • Acute Gout
  • Chronic Gout
• By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GOUT THERAPEUTICS MARKET, BY DRUG CLASS

5.1. Introduction

5.2. NSAIDs

5.3. Corticosteroids

5.4. Colchicine

5.5. Urate-Lowering Agents

5.6. Others

6. GOUT THERAPEUTICS MARKET, BY DISEASE CONDITION

6.1. Introduction

6.2. Acute Gout

6.3. Chronic Gout

7. GOUT THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Hospital Pharmacy

7.3. Retail Pharmacy

7.4. Online Pharmacy

8. GOUT THERAPEUTICS MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Takeda Pharmaceutical Company Ltd.

10.2. Novartis AG

10.3. AstraZeneca plc

10.4. Horizon Therapeutics plc

10.5. Merck & Co. Inc.

10.6. Teijin Pharma Ltd.

10.7. GlaxoSmithKline, Plc.

10.8. Arthrosi

10.9. Mayo Clinic

10.10. Johns Hopkins Arthritis Center

Takeda Pharmaceutical Company Ltd.

Novartis AG

AstraZeneca plc

Horizon Therapeutics plc

Merck & Co. Inc.

Teijin Pharma Ltd.

GlaxoSmithKline, Plc.

Arthrosi

Mayo Clinic

Johns Hopkins Arthritis Center